Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Biotech

Biotech

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • FDA
  • General
  • Health Care
  • Large Cap
  • Movers
  • News
  • Trading Ideas

Why Is Philips Stock Trading Lower Today?

By Vandana Singh
November 29, 11:12 AM
Tuesday, the FDA issued a warning to patients and healthcare providers to carefully monitor 

PHG

Read More
1 minute read
  • Biotech
  • General
  • News

Elevai Labs Enters Into Licensing Agreement With Yuva Biosciences To Combine Exosome And Mitochondrial Technologies To Develop New Aesthetics Products

By Benzinga Newsdesk
November 29, 10:05 AM
Elevai Labs, Inc. (NASDAQ:ELAB) a medical aesthetic company specializing in physician-dispensed skincare, today announced that they have signed a licensing agreement with Yuva Biosciences, Inc. to research and develop

ELAB

Read More
3 minute read
  • Biotech
  • General
  • News

AWS And Accenture Help Merck Use Cloud Technology To Reduce Drug Discovery Time And Accelerate Clinical Trial Development

By Benzinga Newsdesk
November 29, 10:02 AM
Leading biopharmaceutical company taps AWS and Accenture for technology modernizationAt AWS re:Invent, Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ:AMZN), today announced it is working with

ACN

Read More
2 minute read
  • Biotech
  • General
  • News

SELLAS Life Sciences Reaches Target Enrollment ex-China In Phase 3 REGAL Trial Of Galinpepimut-S In Acute Myeloid Leukemia

By Benzinga Newsdesk
November 29, 9:45 AM
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today

SLS

Read More
4 minute read
  • Biotech
  • General
  • News

Clinical Validation Data Published In CHEST Demonstrate That Veracyte’s Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment For Patients With Lung Nodules

By Benzinga Newsdesk
November 29, 9:35 AM
Non-invasive genomic test is designed to help physicians guide next steps for current and former smokers with lung nodulesVeracyte, Inc. (NASDAQ:VCYT) announced that clinical validation data published in the journal

VCYT

Read More
2 minute read
  • Biotech
  • General
  • News

Interim Results From Ongoing Clinical Study Confirm EB613 Optimized Profile For Osteoporosis Treatment And Potential For Entera’s Next Generation Oral Peptide Platform

By Benzinga Newsdesk
November 29, 9:33 AM
Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and therapeutic proteins, reported today interim data from an ongoing Phase 1 study designed to assess

ENTX

Read More
2 minute read
  • Biotech
  • FDA
  • General
  • News

Dyadic Announces Top-Line Results From Its Successful Phase 1 Clinical Trial For A First-In-Human Filamentous Fungal-Based Vaccine Candidate; Primary Endpoint Met

By Benzinga Newsdesk
November 29, 9:32 AM
Primary endpoint metDemonstrated safety and reactogenicity of DYAI-100 recombinant proteinC1-cell produced antigen was both safe and well-toleratedNo Serious Adverse Events reportedFinal Clinical Study Report available

DYAI

Read More
2 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • Large Cap
  • News
  • Penny Stocks

Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies

By Vandana Singh
November 29, 9:30 AM
Tuesday, the FDA said it received reports of patients developing T-cell malig

BMY

Read More
7 minute read
  • Biotech
  • Events
  • General
  • News

Reported Earlier, Praxis Precision Medicines To Showcase Largest Pipeline Of Precision Epilepsy Programs And Breadth Of Commitment To Epilepsy Treatments At Upcoming Meetings

By Benzinga Newsdesk
November 29, 9:26 AM
Praxis Precision Medicines, Inc.

PRAX

Read More
2 minute read
  • Biotech
  • General
  • News

IceCure’s ProSense Deepens Regulatory Approval In India

By Benzinga Newsdesk
November 29, 9:12 AM
ProSense® is already marketed and sold in India based on previous regulatory requirements and now has been re-classified due to new regulationsBreast cancer cryoablation is already performed in India with

ICCM

Posts pagination

Previous 1 … 188 189 190 … 795 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service